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Innate immunityUnderstanding how single nucleotide polymorphisms (SNPs) lead to disease at a molecular level
provides a starting point for improved therapeutic intervention. SNPs in the innate immune recep-
tor nucleotide oligomerisation domain 2 (NOD2) can cause the inﬂammatory disorders Blau Syn-
drome (BS) and early onset sarcoidosis (EOS) through receptor hyperactivation. Here, we show
that these polymorphisms cluster into two primary locations: the ATP/Mg2+-binding site and helical
domain 1. Polymorphisms in these two locations may consequently dysregulate ATP hydrolysis and
NOD2 autoinhibition, respectively. Complementary mutations in NOD1 did not mirror the NOD2
phenotype, which indicates that NOD1 and NOD2 are activated and regulated by distinct methods.
 2014 The Authors. Published by Elsevier B.V. on behalf of the Federation of European Biochemical
Societies. This is an open access article under the CC BY license (http://creativecommons.org/licenses/
by/3.0/).1. Introduction
Blau syndrome (BS) is a rare autosomal dominant disease
manifesting as a triad of symptoms – rashes, uveitis and arthritis
– between 3 and 4 years of age. BS is associated with gain-of-func-
tion single nucleotide polymorphisms (SNPs) in the NACHT (found
in NAIP, CIITA, HET-E and TP-1) domain of the innate immune
receptor NOD2 (nucleotide oligomerisation domain containing 2)
[1–4]. Patients with the phenotypically similar disease early-onset
sarcoidosis (EOS) possess SNPs in common with BS [4], supporting
the suggestion that EOS is a sporadic, rather than familial, version
of BS [5]. Loss-of-function SNPs in NOD2 have been strongly asso-
ciated with the inﬂammatory bowel condition Crohn’s Disease [6].
NOD2 is a member of the cytosolic NLR (nucleotide-binding,
leucine-rich repeat containing) family of pattern recognitionreceptors [7]. NOD2 is activated by the peptidoglycan component
muramyl dipeptide, following which NOD2 engages the adaptor
receptor interacting protein 2 (RIP2) to initiate pro-inﬂammatory
signalling pathways involving nuclear factor kappa B (NF-jB) and
stress kinases [7–9]. NOD2 plays an important role in the response
to bacterial infection, including the activation of autophagy.
In this work we have analysed 16 currently reported BS or EOS-
associated NOD2 SNPs using NF-jB reporter assays to conﬁrm that
all but two of these result in a hyperactive form of NOD2.
Consistent with an increase in the level of basal signalling the poly-
morphisms show an increased propensity for NOD2 to relocate to
the plasma membrane. Mapping these polymorphisms to a homol-
ogy model of the NOD2 NACHT shows that they cluster around the
helical domain 1 (HD1) and the nucleotide binding pocket. We pro-
pose that this results in dysregulation of NOD2 signalling by
impacting receptor autoinhibition and nucleotide hydrolysis.
2. Results
2.1. Blau syndrome associated NOD2 SNPs show basal hyperactivation
Sixteen NOD2 SNPs associated with BS or EOS (Table 1) were
tested for their impact on NOD2 receptor signalling (Fig. 1). All of
Table 1
NOD2 SNPs investigated in this study reportedly associated with Blau syndrome (BS) or early onset sarcoidosis (EOS). Nd = not determined.
SNP Disease association Reported impact on NOD2 signalling References
R334Q BS/EOS Autoactive [1,3,4]
R334W BS/EOS Autoactive [1,3,4]
E383G BS Autoactive [27]
E383K BS/EOS Autoactive [23]
G464W BS Nd [29]
L469F BS/EOS Autoactive [1,3]
R471C BS/acute myeloid leukemia Nd [24,28]
G481D BS/EOS Autoactive [33]
W490L BS/EOS Nd [23]
C495Y BS/EOS Autoactive [23]
H496L EOS Autoactive [4]
M513T EOS Autoactive [4]
R587C BS Nd [24]
T605N BS Nd [34]
T605P EOS Autoactive [4]
N670K EOS Autoactive [4]
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Fig. 1. Blau syndrome single nucleotide polymorphisms result in NOD2 hyperactivity. Hyperactive NACHT SNPs were assayed for NF-jB activity in the (A) absence or (B)
presence of MDP. Assays were performed in HEK293 cells on 96 well plates. Cells were transfected with 0.1 ng of the relevant pCMV-FLAG-NOD2 plasmid and lysed 24 h later.
Graphs are coloured as follows: light green – no signiﬁcant difference to wildtype; blue – a signiﬁcant hyperactive response; purple – a signiﬁcant reduction in the degree of
receptor signalling. In panel (B) open bars represent unstimulated samples and chequered bars represent stimulation with 100 ng/ml of MDP. Error bars denote standard error
of the mean and statistical signiﬁcance is denoted by asterisks (⁄=<0.05, ⁄⁄=<0.01, ⁄⁄⁄=<0.001). (C) HEK293 cells in 12 well plates were transfected with 1 lg of the appropriate
pCMV-FLAG-NOD2 plasmid. After 24 h, lysates were western blotted with mouse anti-FLAG and mouse anti-GAPDH primary antibodies and goat anti-mouse secondary
antibody.
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Fig. 2. Differential behaviour of complementary mutations to the Blau syndrome
polymorphisms in the related NLR protein NOD1. NOD1 NACHT SNPs were assayed
for NF-jB activity in the absence (A) or presence (B) of the NOD1 ligand ie-DAP.
Assays were performed in HEK293 cells on 96 well plates. Cells were transfected
with 0.1 ng of the relevant pCMV-FLAG-NOD1 plasmid (+/ ligand) and lysed 24 h
later. Graphs are coloured as follows: light green – no signiﬁcant difference to
wildtype; blue – a signiﬁcant hyperactive response; purple – a signiﬁcant reduction
in the degree of receptor signalling. In panel (B) open bars represent unstimulated
samples and chequered bars represent stimulation with 100 ng/ml of ie-DAP Error
bars denote standard error of the mean and statistical signiﬁcance is denoted by
asterisks (⁄=<0.05, ⁄⁄=<0.01, ⁄⁄⁄=<0.001). (C) HEK293 cells in 12 well plates were
transfected with 1 lg of the appropriate pCMV-FLAG-NOD1 plasmid. After 24 h,
lysates were western blotted with mouse anti-FLAG and mouse anti-GAPDH
primary antibodies and goat anti-mouse secondary.
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NOD2-mediated NF-kB signalling were hyperactive in the absence
of ligand stimulation (Fig. 1A) conﬁrming the robustness of our
reporter assay. Three of the ﬁve uncharacterised SNPs (G464W,
W490L and T605N) were also hyperactive (Fig. 1A). However, nei-
ther R471C nor R587C produced a hyperactive response. None of
the SNPs responded in a hyperactive manner following ligand
stimulation (Fig. 1B). Whilst most SNPs showed a slightly
enhanced signalling response in the presence of MDP, four of them
(E383G, E383K, W490L, and M513T), showed a signiﬁcantly
impaired response to ligand compared to the wild-type receptor
(Fig. 1B). All of the SNPs expressed at comparable levels to wild-
type NOD2 (Fig. 1C).
The behaviour of R471C and R587C contrasts with all other BS-
associated SNPs and does not ﬁt the hyperactive NOD2 phenotype
described for BS raising the possibility that these are not true BS-
associated NOD2 SNPs. We compared the sequence of the NOD2
NACHT across ﬁfteen different species, including the relatively
divergent platypus and zebraﬁsh (Supplementary Fig. 1). R334,
E383, G481, W490, C495 and T605 are conserved across all ﬁfteen
species; H496 and M513 differ only in the zebraﬁsh in which they
are conservatively changed to tyrosine and valine respectively;
whilst G464 and L469 are conserved in the placental mammals
but differ in the platypus and zebraﬁsh. In stark contrast R471
and R587 are highly variable across species, consistent with the
limited functional impact upon mutation suggesting that they
may not actually be disease associated.
2.2. NOD1 and NOD2 show different functional phenotypes
It has been proposed that whilst both NOD1 and NOD2 utilise
ATP hydrolysis for receptor activation NOD2 additionally requires
ATP hydrolysis for receptor deactivation [10,11]. Consistent with
this when the corresponding mutation to E383K (extended
Walker-B motif) was made in NOD1 it did not lead to a hyperactive
response, instead causing a decrease in NF-jB signalling [10]. We
chose to further investigate the parallels between NOD1/2 activa-
tion by making mutations in NOD1 corresponding to a broader
range of eight different BS/EOS SNPS.
Consistent with the work of Zurek and colleagues NOD1 E288K
(equivalent to NOD2 E383K) resulted in a severe decrease in both
basal and ligand-stimulated NOD1 NF-jB activity (Fig. 2A and B).
Two additional mutations, A369W and V424T (equivalent to
NOD2 G464W and M513T) showed a decrease in basal activity
but showed a partial response to the addition of ie-DAP (Fig. 2A
and B). Meanwhile F401L (NOD2H496L) behaved in amanner com-
parable to wild-type NOD1. Interestingly R237Q, D287E, W395L
and T519N (corresponding to NOD2 R334Q, D382E, W490L and
T605N) all exhibited a hyperactive response (Fig. 2A) and all have
wild-type residues identical between NOD1 and NOD2. With the
exception of T519N, which had slightly reduced expression, all
NOD1 mutants showed a broadly similar expression level to the
wild-type receptor (Fig. 2C). These results suggest that NOD1 is less
susceptible to SNP induced hyperactivation, consistent with a dif-
ferent mechanism of functional regulation compared to NOD2.
2.3. BS SNPs show increased recruitment to the plasma membrane
Activation of NOD2, and NOD1, has been shown to result in
relocalisation of the receptor to the plasma and/or endosomal
membranes fromwhere it is believed to form signalling-competent
complexes [12–16]. We used subcellular fractionation to compare
the proportion of the NOD2 BS/EOS SNPs in the membrane and the
cytoplasmic fractions (Fig. 3A). All hyperactive SNPs were present
in the membrane fraction unlike the signalling defective control
Crohn’s Disease associated SNP fs1007incC (Fig. 3A). Consistentwith previous work [10] the proportion of hyperactive NOD2 at
the membrane appeared enhanced in comparison to the wild-type
protein. Immunoﬂuorescence on a selection of the hyperactive
SNPs conﬁrmed the membrane association of these constructs
(Fig. 3B).
2.4. Hyperactive SNPS map to distinct regions of the NOD2 NACHT
It has been suggested that the hyperactivity of the NOD2 E383K
BS SNP results from an inhibition of ATP hydrolysis [10]. However,
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Fig. 3. Hyperactive NOD2 Blau syndrome single nucleotide polymorphisms show increased recruitment to the cellular membrane. (A) Subcellular fractionation of HEK293T
cells transiently transfected with NOD2 BS/EOS SNPs showed membrane recruitment for all constructs. NOD2 constructs were detected using an anti-FLAG antibody. GAPDH
was found only in the cytoplasmic fraction conﬁrming the purity of the separation. (B) Selected NOD2 BS/EOS SNPs were visualised by immunoﬂuorescence following
transient transfection of HeLa cells.
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tivity of all the other BS/EOS SNPs tested. We generated a molecu-
lar model of the NOD2 NACHT and mapped the position of the SNPs
(Fig. 4A) except for N670 K as the template alignment of the NOD2
HD2 region was too ambiguous to model. The BS/EOS SNPs cluster
into two distinct patches: one surrounding the magnesium and
ATP binding sites (Fig. 4A and B), and the other on HD1 (Fig. 4A
and C). This second patch consists of internal resides within HD1
and two surface glycines (Fig. 4C). The two non-hyperactive SNPs
are located on the surface of HD1 (R471C) and in a loop region dis-
tal to either patch (R587C). Mapping the corresponding NOD1
mutations onto a model of the NOD1 NACHT domain revealed
the same pattern of clustering (Fig. 4D).
Building on earlier studies [17,18] alignments of the NOD1 and
NOD2 NACHTs with NLRP3 and CIITA, both of which possess
hyperactive SNPs; and with NLRC4, the only NLR for which the
structure of the NACHT has been solved [19] were made. Reﬂective
of their likely functional role residues, including R334, D382 and
E383, around the Mg2+/ATP binding patch are predominantly con-
served across these NLRs (Fig. 5). This includes two of the NLRP3
SNPs, R260W and D303N (NOD2 R334 and D382), which are asso-
ciated with cryopyrin-associated periodic syndromes (CAPS) gain
of function diseases Muckle–Wells syndrome and Neonatal Onset
Multisystem Inﬂammatory Disease [20]. Other NLRP3 SNPS are
mainly spread throughout the a/b Rossman fold sub-domain. The
NOD2 SNPs in HD1 show limited conservation with only L469,
C495 and M513 being conservatively substituted with hydropho-
bic residues in the other NLRs. This suggests that the importanceof HD1 for the regulation of NOD2 signalling may be unique
amongst NLRs.3. Discussion
We have studied SNPs in the NACHT domain of the pattern rec-
ognition receptor NOD2 associated with BS and EOS to determine
the molecular basis of disease. Hyperactive polymorphisms cluster
in two distinct patches in the NOD2 NACHT, one surrounding the
ATP/Mg2+ binding site and one in the HD1 domain. Complementary
mutations in NOD1 did not all result in hyperactivation providing
further evidence for a differential mechanism of receptor regula-
tion between NOD1 and NOD2.
The positional grouping of the NOD2 BS/EOS SNPs (Fig. 4) pro-
vides a clear functional insight into how they cause disease. SNPs
in the Mg2+/ATP patch disrupt ATP hydrolysis, a process essential
to convert the receptor back to an inactive ADP-bound state [11].
Disruption of ATP binding can deactivate the receptor whereas
deregulation of ATP hydrolysis can induce hyperactivation by trap-
ping the receptor in an active state. We propose that SNPs in the
ATP/Mg2+ patch, including R334Q/W, E383G/K, W490L and
T605N/P, inhibit the ATP/ADP cycling required to deactivate
NOD2. R334 and E383 are modelled in close contact with the
Mg2+ ion and are therefore directly important for hydrolysis.
Whilst T605 doesn’t directly contact the ATP or Mg2+ ion it is close
to the conserved histidine, H603, which acts as Sensor II for ATP
binding/hydrolysis [17] and which when mutated causes NOD2
Fig. 4. Blau syndrome susceptibility polymorphisms are found in two distinct
regions of the NOD2 NACHT. (A) Location of hyperactive/BS SNPs mapped on a
model of the NOD2 NACHT. The alpha carbon is represented as a sphere and colour
coded as follows: green – signals comparable to wildtype; blue – hyperactive
located in ATP/ Mg2+ patch; pink – hyperactive located in HD1 patch. (B) Close up of
the ATP/Mg2+ patch. Conserved residues important in nucleotide binding or
hydrolysis are coloured purple. SNPs are coloured blue. R334 and E383 are in close
contact with the Mg2+ and linked to priming H2O for hydrolysis of the ATP molecule.
W490 and T605 are not directly in contact with the ATP or Mg2+ but T605 is in close
proximity to the conserved H603. (C) Close up of the HD1 patch. SNPs located
within HD1 are highlighted in pink. These include: G464, L469, G481, C495, H496
and M513. Of these residues L469, C495, H495 and M513 are all internal residues
within the domain. G464 and G481 are surface glycines. The wild-type like SNP,
R471, is highlighted in green. (D) Location in the NOD1 NACHT of the complemen-
tary mutations in NOD1. The alpha carbon is represented as a sphere and colour
coded as follows: blue – hyperactive mutations located in the ATP/Mg2+ patch; pink
– E288 K, an inactive mutant which also resides in the ATP/Mg2+ patch; green –
mutations in the HD1 patch which gave a wild-type response; orange – mutations
which were not made. In each panel the ATP molecule and Mg2+ ion are shown in
black stick representation and as a black sphere respectively.
3386 R. Parkhouse et al. / FEBS Letters 588 (2014) 3382–3389hyperactivation [10]. We suggest that the T605N/P SNPs interfere
with hydrolysis by spatially disrupting H603.
Meanwhile, SNPs in HD1, and potentially HD2, may interfere
with the receptor autoinhibition. HD1 houses the GxP motif which
functions to hold the nucleotide in position and HD2 in NLRC4 con-
tacts the LRR in the inhibited conformation [21,19]. We hypothe-
sise that the HD1 SNPs trap the receptor in an active state by
inhibiting formation of the closed, inactive conformation with
the LRR folded back onto the NACHT. It is therefore tempting to
speculate that the HD1 and HD2 sub-domains act as hinges, chang-
ing the conformation of the protein between active and inactive
states. Interestingly a region of the murine NAIP proteins encom-
passing both HD1 and HD2 was shown to be crucial for ligand
speciﬁcity and activation of the NAIP/NLRC4 inﬂammasome [22].
Differences between the modes of activation for NOD1 and
NOD2 have been previously reported [10]. Whilst Zurek and col-
leagues did not report any hyperactive NOD1 mutations we have
shown that certain mutations in the NOD1 ATP/Mg2+ binding patch
induce hyperactivity (Fig. 2) supporting an important role for
hydrolysis in NOD1 regulation. Clear differences exist in the regu-
lation of NOD1 and NOD2. For example, mutation of the acidic res-
idue, E288, in the extended Walker-B motif of NOD1 results in an
inactive response, whereas in NOD2 mutating the equivalent resi-
due, E383, results in a hyperactive receptor. Similarly, mutations in
HD1 of NOD1 do not interfere with receptor signalling, whereas
the equivalent NOD2 SNPS are hyperactive.
Two SNPs associated with BS, R471C and M587C [23,24], elic-
ited a wild-type response (Fig. 1). Neither of these SNPs is located
in the HD1 or ATP/Mg2+ patches identiﬁed and lack conservation
across different species. Together these cast doubt on the validity
of their association with BS. However, NOD2 is the only gene asso-
ciated with BS, so if these SNPs fail to elicit a hyperactive response
maybe other NOD2 SNPs are present in the same patients, although
neither study reported this [23,24]. Comparison of NLRP3 muta-
tions associated with CAPS conditions demonstrated that some of
these hyperactive mutations could be located in and around the
ATP/Mg2+ binding site suggesting that their dysfunction may also
relate to altered nucleotide hydrolysis. However, other SNPs were
more spread across the a–b Rossman fold suggesting that there
may be additional or alternative mechanisms at play in those
examples.
The spatial groupings of the NOD2 BS/EOS SNPs we have
described, coupled with the functional insight, provide a clear
improvement in our understanding of how NOD2 dictates disease
pathogenesis in both BS and EOS. Patients with either R334Q or
R334W polymorphisms experience the most severe disease symp-
toms [25] suggesting that disruption of the nucleotide hydrolysis
function is more consequential than interference with
autoinhibition.
4. Materials and methods
4.1. Chemicals, antibodies and general methods
Chemical reagents were obtained from Sigma–Aldrich, UK,
unless otherwise speciﬁed. HEK 293T cells were maintained in
DMEM supplemented with 10% Foetal Calf Serum, 100 lg/ml Pen-
icillin/Streptomycin and 2 mM L-glutamine at 37 C and 5% CO2. All
transfections were performed using jetPEI™ (Polyplus-Transfec-
tion) as per the manufacturers’ instructions. Antibodies used in this
work were: rabbit anti-FLAG (F7425, Sigma–Aldrich), mouse anti-
FLAG M2 (F3165, Sigma–Aldrich), mouse anti-V5 (ab27671;
Abcam), mouse anti-GAPDH (ab9485, Abcam), rabbit anti-Myc
(ab9106, Abcam), goat anti-rabbit (ab6721, Abcam) and goat
anti-mouse (A4416, Sigma–Aldrich).
Fig. 5. Phyre2 based alignment of NACHT domains from human NOD1, NOD2, NLRP3, CIITA and NLRC4. SNPs in NOD2 associated with BS and leading to a hyperactive
response are highlighted and labelled in red. The corresponding mutations in NOD1 are named in purple and highlighted in red (hyperactive), green (like wild-type), or blue
(inactive). SNPs in NLRP3 associated with cryopyrin-associated periodic syndromes are highlighted in yellow. The three NACHT sub-domains are marked and conserved
functional features are highlighted in grey.
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pCMV-FLAG-NOD1 and pMV-FLAG-NOD2, encoding N-termi-
nally FLAG-tagged full length NOD1/2 respectively, were a kind gift
from Dr. Thomas Kufer [26]. Blau syndrome susceptibility SNPs
were identiﬁed using published literature [1,3,4,23,24,27–29] and
the NCBI SNP database and generated using site directed mutagen-
esis. Mutant sequences were veriﬁed by DNA sequencing of the
entire open reading frame. pLuc encoding Fireﬂy luciferase under
the control of an NF-jB promoter and phrG encoding Renilla lucif-
erase controlled by a constitutive promoter were kind gifts from
Prof Clare Bryant.
4.3. NF-kB reporter assays
HEK293T cells in 96 well plates were transfected with: 2 ng
pLuc, 1 ng phrG, 0.1 ng wild-type or mutant pCMV-FLAG-NOD2,
and made up to 0.1 lg total DNA with empty plasmid. 100 ng/ml
MDP or ie-DAP (both Invivogen) was added concomitant with
transfection. Cells were lysed 24 h post transfection with 1x pas-
sive lysis buffer (Promega) and luminescence measured with a
LUMIstar Luminometer (BMG Labtech). Protein expression was
checked 24 h after transfection.
4.4. Subcellular fractionation
HEK 293 cells seeded in 12 well plates were transfected with
1 lg of wild-type or mutant pCMV-FLAG-NOD2 incubated
overnight. Cytosolic and membrane fractions were isolated using
a Subcellular Protein Fractionation Kit (Perbio Science UK).
Fractions were analysed by SDS–Page and western blotting.
4.5. Immunoﬂuorescence
HeLa cells were seeded into 12 well plates containing a steril-
ised 19 mm diameter glass coverslip, transfected with 1 lg of
wild-type or mutant pCMV-FLAG-NOD2 and incubated overnight
before washing with 1 PBS and ﬁxing with 4% Paraformaldehyde
in PBS for 15 min. Cells were washed again (1 PBS) and permea-
bilised with 0.4% Triton X-100 (VWR) in 1 PBS for 10 min. Block-
ing was performed for 20 min using 2.5% goat serum and 1% bovine
serum albumin in 1 PBS. Samples were incubated with mouse
anti-FLAG primary antibody diluted 1:500 in blocking buffer for
1 h, washed 3 times with 1 PBS and incubated with Alexa Fluor
 488 goat anti-mouse IgG (Life Technologies) for 1 h. Cells were
washed 3 times with 1 PBS, the second wash containing a
1:5000 dilution of 10 mg/ml Hoechst 33258 in PBS to stain the
nucleus. Coverslips were mounted onto microscope slides (VWR)
using Mowiol mounting solution containing 2.5% 1,4-Diazabicyclo
[2.2.2] octane to reduce fading. Cells were visualised using an AXIO
Imager.M2 microscope (Carl Zeiss Ltd., Cambridge, UK) and images
created using Image J.
4.6. Bioinformatics
The NACHT regions of NOD2 from human (Homo sapien;
NP_071445.1);macaque (Macacamulatta; XP_001084287.1);mouse
(Mus musculus; NP_665856.2); boar (Sus scrofa; NP_001098765.1);
cow (Bos taurus; NP_001002889.1); dog (Canis lupus familiaris;
XP_544412.3); guinea pig (Cavia porcellus; XP_003477732.1); ham-
ster (Cricetulus griseus; XP_003499558.1); horse (Equus caballus;
XP_001915323.2); rabbit (Oryctolagus cuniculus; XP_002721391.1);
elephant (Loxodonta africana; XP_003416420.1); platypus (Ornitho-
rhynchus anatinus; XP_001519938.1); and zebraﬁsh (Danio rerio;
XP_697924.3) were aligned usingMuscle [30]. Phyre2 [31] was used
to generate an accurate alignment between the NACHTS of humanNOD1 (AAD28350.1), NOD2, NLRP3 (AAI43360.1), CIITA
(NP_001273331.1) and NLRC4 (NP_001186068.1).
Generation of a homology model of the NOD2 NACHT covering
residues A217-C632 using the NACHT of NLRC4 (PDB: 4KXF; [19])
as a template has been described previously [32]. A homology
model of the NOD1 NACHT was generated by the same approach.Acknowledgements
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